Initial Public Offer now closed.
The Board of Cannasouth Limited is pleased to advise that its public offer of shares has closed oversubscribed today.
Cannasouth was seeking to raise a minimum of $5 million (10 million new ordinary shares) and a maximum of $10 million (20 million new ordinary shares) through a Priority Offer of $5m which closed on June 7, and a General Offer of $5m which closed oversubscribed at 5pm today.
Any applications received for the General Offer after today’s close will not be accepted and will be returned to investors.
Welcome to Cannasouth, a biopharmaceutical company dedicated to the development of medicinal cannabis treatment options for clinicians, doctors and patients.
Cannasouth medicinal cannabis products will be manufactured from naturally grown medicinal cannabis cultivated in New Zealand without herbicides or pesticides.
Our products will be produced under GMP & ISO using environmentally friendly methods without the use of harmful chemicals or solvents, ensuring patients are treated with pure cannabinoid therapeutic compounds of the highest quality.
Cannasouth provides information, educational material and media for specialists, doctors, and clinicians enabling informed patient treatment choices.
Supporting patient access to high quality educational material regarding cannabinoid therapeutics is central to meaningful health outcomes.
Our investors are critical to the success of the company. We acknowledge the special trust they place in us with our commitment to the expansion of Cannasouth.